Based on the key indicators related to Larimar Therapeutics' liquidity, profitability, solvency, and operating efficiency, Larimar Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Larimar Therapeutics' Total Liabilities is relatively stable compared to the past year. As of 03/23/2025, Total Current Assets is likely to grow to about 83.9 M, while Other Current Liabilities is likely to drop slightly above 6.7 M. Key indicators impacting Larimar Therapeutics' financial strength include:
The financial analysis of Larimar Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Larimar Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Larimar Therapeutics competes with Vaxcyte, Syndax Pharmaceuticals, Merus BV, Sutro Biopharma, and Immuneering Corp. Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreichs ataxia, a rare, progressive, and fatal genetic disease. Larimar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Larimar Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Larimar Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Larimar Therapeutics's current stock value. Our valuation model uses many indicators to compare Larimar Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Larimar Therapeutics competition to find correlations between indicators driving Larimar Therapeutics's intrinsic value. More Info.
Larimar Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Larimar Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Larimar Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Larimar Therapeutics Systematic Risk
Larimar Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Larimar Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Larimar Therapeutics correlated with the market. If Beta is less than 0 Larimar Therapeutics generally moves in the opposite direction as compared to the market. If Larimar Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Larimar Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Larimar Therapeutics is generally in the same direction as the market. If Beta > 1 Larimar Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Larimar Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Larimar Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Larimar Therapeutics growth as a starting point in their analysis.
Larimar Therapeutics March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Larimar Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Larimar Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Larimar Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Larimar Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Larimar Therapeutics's daily price indicators and compare them against related drivers.
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.